CUMYL-CH-MEGACLONE
Appearance
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C27H30N2O |
Molar mass | 398.550 g·mol−1 |
3D model (JSmol) | |
| |
|
CUMYL-CH-MEGACLONE (CUMYL-CHMGACLONE, SGT-270) is a gamma-carboline based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Hungary in December 2018.[1][2][3]
See also
- 5F-CUMYL-PEGACLONE
- CUMYL-5F-P7AICA
- CUMYL-CB-MEGACLONE
- CUMYL-BC-HPMEGACLONE-221
- CUMYL-CBMINACA
- CUMYL-THPINACA
References
- ^ Alam RM, Keating JJ (March 2020). "Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists". Drug Testing and Analysis. 12 (3): 297–315. doi:10.1002/dta.2752. PMID 31854124. S2CID 209417068.
- ^ Haschimi B, Giorgetti A, Mogler L, Nagy TZ, Kramer S, Halter S, et al. (June 2020). "The Novel Psychoactive Substance Cumyl-CH-MEGACLONE: Human Phase-I Metabolism, Basic Pharmacological Characterization, and Comparison to Other Synthetic Cannabinoid Receptor Agonists with a γ-Carboline-1-one Core". Journal of Analytical Toxicology. 45 (3): 277–290. doi:10.1093/jat/bkaa065. PMID 32514544.
- ^ Institóris L, Kovács K, Sija É, Berkecz R, Körmöczi T, Németh I, Elek I, Bakos Á, Urbán I, Pap C, Kereszty É (June 2021). "Clinical symptoms and blood concentration of new psychoactive substances (NPS) in intoxicated and hospitalized patients in the Budapest region of Hungary (2018-19)". Clinical Toxicology. 60 (1). Philadelphia, Pa.: 18–24. doi:10.1080/15563650.2021.1928162. PMID 34080493. S2CID 235321374.